Brind.

Market Comparison Highlights Differences Between Teleflex and Trinity Biotech

1 report, 1 independent Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A market comparison was conducted between Teleflex and Trinity Biotech, two healthcare companies. The analysis contrasted the companies based on factors including profitability, valuation, institutional ownership, and analyst recommendations. The report noted that analysts view Teleflex as more favorable due to its stronger consensus rating and higher probable upside.

From tickerreport.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights differences in investment profiles, such as volatility and ownership structure. Trinity Biotech has a beta of 0.73, while Teleflex has a beta of 0.83. Teleflex also has a higher percentage of institutional ownership at 95.6% compared to Trinity Biotech's 79.0%.

From tickerreport.com

Who's involved

  • TeleflexAmerican medical device company that is being compared in the market

Keep exploring

The entities involved

  • Teleflex

    American medical device company

    Nothing else this week.

Coverage

Newest first; wire copies grouped